Lihong Zhu
Research Subjects
Research Interests
Lihong Zhu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Le Zhang
Department of Neonatology, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China; Clinical Research Center, Affiliated Children's Hospital of Jiangnan University, Wuxi Children's Hospital, Jiangsu Provincial Industrial Technology Engineering Center for Pediatric Metabolic Disease Prevention and Control, Wuxi Key Laboratory of Genetic and Metabolic Diseases in Children, Wuxi 214023, Jiangsu, China
3 shared publications Mengyuan Hu
Department of Paediatrics, Jinhua Maternal and Child Health Hospital, Jinhua, P. R. China
2 shared publicationsCai Tang
Department of Pediatric Laboratory, Wuxi Children's Hospital, Affiliated Children's Hospital of Jiangnan University, Wuxi, 214023, Jiangsu, China
1 shared publicationCongwei You
Department of Pediatric Laboratory, Wuxi Children's Hospital, Affiliated Children's Hospital of Jiangnan University, Wuxi, 214023, Jiangsu, China
1 shared publicationFan Yang
Department of Paediatric Laboratory, Affiliated Children’s Hospital of Jiangnan University, Wuxi Children’s Hospital, Wuxi, P. R. China
1 shared publication- Fan Yang
Department of Pediatric Laboratory, Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 26 May 2026
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 31 (1)
Association between chrononutrition patterns and metabolic dysfunction-associated steatotic liver disease in adolescents: a population-based study
Previous studies have primarily examined the benefits of calorie restriction and fasting for metabolic dysfunction-associated steatotic liver disease (MASLD). However, the impacts of eating timing and frequency on MASLD remain uncertain. This study comprised 2128 participants aged 12 to 19 years, drawn from the National Health and Nutrition Examination Survey (NHANES) data collected during the period 2017 to 2023. Chrononutrition patterns were determined with two 24-h dietary recalls. Logistic regression, accounting for potential confounders, was used to examine the relationship between chrononutrition patterns and MASLD. Subgroup analyses stratified by demographic and clinical variables were used to evaluate their potential impact on the associations observed. Mediation analysis was conducted to assess the indirect effects of metabolic indicators on MASLD risk. Logistic regression demonstrated that the timing of the first (continuous: OR: 1.07; 95% CI 1.02-1.14) and midpoint (continuous: OR: 1.11; 95% CI 1.00-1.22) food/beverage intake, as well as energy intake at dinner (OR: 1.01; 95% CI 1.00-1.01), were significantly associated with an increased risk of MASLD. Furthermore, the eating window (continuous: OR: 0.95; 95% CI 0.91-0.99) was significantly negatively correlated with the risk of MASLD. Subgroup analyses revealed that the chrononutrition pattern was particularly linked to an elevated risk of MASLD among males and Mexican Americans (P < 0.05). Additionally, HDL-C and NHHR (58.69% and 61.90%, respectively) partially mediated the association between the timing of the first food/beverage intake and MASLD risk. Later timing of the first and midpoint food and beverage intake, as well as greater energy consumption at dinner, are linked to an elevated risk of MASLD. HDL-C and NHHR serve as mediators in these associations, particularly with respect to the timing of the first food or beverage intake.
- 26 May 2026
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 31 (1)
Open AccessAssociation between chrononutrition patterns and metabolic dysfunction-associated steatotic liver disease in adolescents: a population-based study
Previous studies have primarily examined the benefits of calorie restriction and fasting for metabolic dysfunction-associated steatotic liver disease (MASLD). However, the impacts of eating timing and frequency on MASLD remain uncertain. This study comprised 2128 participants aged 12 to 19 years, drawn from the National Health and Nutrition Examination Survey (NHANES) data collected during the period 2017 to 2023. Chrononutrition patterns were determined with two 24-h dietary recalls. Logistic regression, accounting for potential confounders, was used to examine the relationship between chrononutrition patterns and MASLD. Subgroup analyses stratified by demographic and clinical variables were used to evaluate their potential impact on the associations observed. Mediation analysis was conducted to assess the indirect effects of metabolic indicators on MASLD risk. Logistic regression demonstrated that the timing of the first (continuous: OR: 1.07; 95% CI 1.02-1.14) and midpoint (continuous: OR: 1.11; 95% CI 1.00-1.22) food/beverage intake, as well as energy intake at dinner (OR: 1.01; 95% CI 1.00-1.01), were significantly associated with an increased risk of MASLD. Furthermore, the eating window (continuous: OR: 0.95; 95% CI 0.91-0.99) was significantly negatively correlated with the risk of MASLD. Subgroup analyses revealed that the chrononutrition pattern was particularly linked to an elevated risk of MASLD among males and Mexican Americans (P < 0.05). Additionally, HDL-C and NHHR (58.69% and 61.90%, respectively) partially mediated the association between the timing of the first food/beverage intake and MASLD risk. Later timing of the first and midpoint food and beverage intake, as well as greater energy consumption at dinner, are linked to an elevated risk of MASLD. HDL-C and NHHR serve as mediators in these associations, particularly with respect to the timing of the first food or beverage intake.
- Open Access
- 22 January 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-13
Potential alternative and novel biomarkers for paediatric MAFLD: exploratory evidence from a Chinese cohort
Background: While the associations between pediatric non-obese metabolic dysfunction-associated fatty liver disease (MAFLD) and multiple diagnostic biomarkers are well-established, the role of a broader range of blood-based, urine-based, and body composition-based biomarkers for monitoring MAFLD are needed. Methods: A pediatric cohort was established in Wuxi, China. We measured body composition biomarkers, blood-based and urine-based biomarkers, and liver stiffness in participants to diagnose MAFLD and identify alternative and novel potential biomarkers for MAFLD. Body mass index (BMI), high-density lipoprotein cholesterol (HDLC), triglycerides, glucose, systolic blood pressure (SBP), diastolic blood pressure (DBP), and waist perimeter were used as MAFLD diagnostic biomarkers. To identify alternative biomarkers, we performed correlation analysis to determine biomarkers exhibited strong correlation (|r| > 0.8, p-value < 0.05) with diagnostic biomarkers. To identify novel potential biomarkers, we performed regression analysis to determine biomarkers associated with MAFLD (p-value < 0.05 in stepwise multivariate regression) among the remaining biomarkers that are not related to the diagnostic biomarkers. Results: Out of 1,108 participants who completed all examinations (N biomarker = 91), 113 participants were diagnosed with MAFLD (prevalence: 14.99% in boys and 5.18% in girls). 27 biomarkers that were strongly correlated with diagnostic biomarkers were identified as alternative biomarkers. A multivariate logistic regression analysis identified 9 novel potential biomarkers including 5 blood-based biomarkers (plateletocrit, calcium, insulin, AST/ALT ratio, total bilirubin), urine pH, and body fat measurements in the arm, leg, and thigh. Conclusions: This study illustrated the characteristics and potential alternative and novel biomarkers of MAFLD based on a Chinese paediatric cohort. These findings posed new paths in guiding the prevention and early diagnosis and prevention. Trial registration: This trial was registered in the Chinese Clinical Trials Registry (ChiCTR2400080508). The date of first registration, 01/31/2024. Retrospectively registered.
- 22 January 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-13
Open AccessPotential alternative and novel biomarkers for paediatric MAFLD: exploratory evidence from a Chinese cohort
Background: While the associations between pediatric non-obese metabolic dysfunction-associated fatty liver disease (MAFLD) and multiple diagnostic biomarkers are well-established, the role of a broader range of blood-based, urine-based, and body composition-based biomarkers for monitoring MAFLD are needed. Methods: A pediatric cohort was established in Wuxi, China. We measured body composition biomarkers, blood-based and urine-based biomarkers, and liver stiffness in participants to diagnose MAFLD and identify alternative and novel potential biomarkers for MAFLD. Body mass index (BMI), high-density lipoprotein cholesterol (HDLC), triglycerides, glucose, systolic blood pressure (SBP), diastolic blood pressure (DBP), and waist perimeter were used as MAFLD diagnostic biomarkers. To identify alternative biomarkers, we performed correlation analysis to determine biomarkers exhibited strong correlation (|r| > 0.8, p-value < 0.05) with diagnostic biomarkers. To identify novel potential biomarkers, we performed regression analysis to determine biomarkers associated with MAFLD (p-value < 0.05 in stepwise multivariate regression) among the remaining biomarkers that are not related to the diagnostic biomarkers. Results: Out of 1,108 participants who completed all examinations (N biomarker = 91), 113 participants were diagnosed with MAFLD (prevalence: 14.99% in boys and 5.18% in girls). 27 biomarkers that were strongly correlated with diagnostic biomarkers were identified as alternative biomarkers. A multivariate logistic regression analysis identified 9 novel potential biomarkers including 5 blood-based biomarkers (plateletocrit, calcium, insulin, AST/ALT ratio, total bilirubin), urine pH, and body fat measurements in the arm, leg, and thigh. Conclusions: This study illustrated the characteristics and potential alternative and novel biomarkers of MAFLD based on a Chinese paediatric cohort. These findings posed new paths in guiding the prevention and early diagnosis and prevention. Trial registration: This trial was registered in the Chinese Clinical Trials Registry (ChiCTR2400080508). The date of first registration, 01/31/2024. Retrospectively registered.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 4627-4639
Protocol for a Longitudinal Cohort Study to Understand Characteristics and Risk Factors Underlying Vibration-Controlled Transient Elastography-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease Children
Background: Metabolic-associated steatotic liver disease (MASLD) is a novel term proposed in 2023 to replace non-alcoholic fatty liver disease (NAFLD) with the aim of better reflecting its pathogenesis and clinical manifestations. Vibration-controlled transient elastography (VCTE) is an evidence-based, non-invasive imaging device used to evaluate liver fat deposition and fibrosis. It can effectively detect liver fat infiltration greater than 5%, which is much higher than the previous ultrasound detection rate (it is difficult to detect liver fat deposition below 30%). Nevertheless, the prevalence and characteristics of MASLD children diagnosed based on these updated criteria are currently not well established. Methods: Currently, a prospective multi-center population-based cohort study is being conducted in Wuxi, China, spanning from 2023 to 2035, involving 5600 children from four primary schools. Throughout the study’s baseline and follow-up periods, yearly physical examinations, laboratory tests, VCTE assessments, and bioelectrical impedance analysis are being conducted to measure MASLD-related biomarkers. Additionally, a questionnaire is being administered to inquire about dietary habits. MASLD is being diagnosed based on clinical and laboratory criteria, and the corresponding prevalence is being assessed. Results: Recruitment began in March 13, 2023. To date, 1475 participants have completed the physical examination and questionnaire survey. Discussion: Our study investigated the prevalence of MASLD and its influencing factors in Chinese school-age children and adolescents. By collecting and analyzing data from physical examinations and survey questionnaires, it may propose new avenues for guiding the treatment and early-stage prevention of MASLD in children. Trial Registration: Chinese Clinical Trials Registry (NO. ChiCTR2400080508).
- 1 December 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 4627-4639
Open AccessProtocol for a Longitudinal Cohort Study to Understand Characteristics and Risk Factors Underlying Vibration-Controlled Transient Elastography-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease Children
Background: Metabolic-associated steatotic liver disease (MASLD) is a novel term proposed in 2023 to replace non-alcoholic fatty liver disease (NAFLD) with the aim of better reflecting its pathogenesis and clinical manifestations. Vibration-controlled transient elastography (VCTE) is an evidence-based, non-invasive imaging device used to evaluate liver fat deposition and fibrosis. It can effectively detect liver fat infiltration greater than 5%, which is much higher than the previous ultrasound detection rate (it is difficult to detect liver fat deposition below 30%). Nevertheless, the prevalence and characteristics of MASLD children diagnosed based on these updated criteria are currently not well established. Methods: Currently, a prospective multi-center population-based cohort study is being conducted in Wuxi, China, spanning from 2023 to 2035, involving 5600 children from four primary schools. Throughout the study’s baseline and follow-up periods, yearly physical examinations, laboratory tests, VCTE assessments, and bioelectrical impedance analysis are being conducted to measure MASLD-related biomarkers. Additionally, a questionnaire is being administered to inquire about dietary habits. MASLD is being diagnosed based on clinical and laboratory criteria, and the corresponding prevalence is being assessed. Results: Recruitment began in March 13, 2023. To date, 1475 participants have completed the physical examination and questionnaire survey. Discussion: Our study investigated the prevalence of MASLD and its influencing factors in Chinese school-age children and adolescents. By collecting and analyzing data from physical examinations and survey questionnaires, it may propose new avenues for guiding the treatment and early-stage prevention of MASLD in children. Trial Registration: Chinese Clinical Trials Registry (NO. ChiCTR2400080508).